Top

Published in:

01-10-2005 | Letter

CYP2D6 genotype and tamoxifen response

Authors: James M Rae, Matthew P Goetz, Daniel F Hayes, James N Ingle, Lang Li, Anna Maria Storniolo, Vered Stearns, David A Flockhart

Published in: Breast Cancer Research | Issue 5/2005

Excerpt

We read with interest the article by Wegman and coworkers [1] entitled 'Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients'. The authors conducted a retrospective analysis of a tamoxifen adjuvant clinical trial and reported that a small subset of patients with estrogen receptor (ER)-positive breast cancer treated with tamoxifen who carried the CYP2D6*4 variant allele did significantly better than patients with the same variants not treated with tamoxifen. …

Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE, Wingreb S: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 2005, 7: R284-R290. 10.1186/bcr993.CrossRefPubMedPubMedCentral

Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Vissche DW, Flockhart DA, Adjei AA, Weinshilboum RM, Couch FJ, et al: Pharmacogenomic determinants of outcome with tamoxifen therapy: findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52. Breast Cancer Res Treat. 2004, 88: S35-

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003, 95: 1758-1764.CrossRefPubMed

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005, 97: 30-39.CrossRefPubMed

Title: CYP2D6 genotype and tamoxifen response
Authors: James M Rae
Matthew P Goetz
Daniel F Hayes
James N Ingle
Lang Li
Anna Maria Storniolo
Vered Stearns
David A Flockhart
Publication date: 01-10-2005
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 5/2005
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1297

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2005

High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area

Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer

Early and late skin reactions to radiotherapy for breast cancer and their correlation with radiation-induced DNA damage in lymphocytes

Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway

Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan

High expression of Lewisy/bantigens is associated with decreased survival in lymph node negative breast carcinomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer